Figure 1.

Cyclophosphamide (CTX) inhibits regulatory T cell (Treg) proliferation and causes a gap in Treg numbers. (A-E) Flow cytometry of CD4+Foxp3+ Treg and CD4+Foxp3- conventional T cells (Tcon) in the spleen (SN), lymph nodes (LN), thymus (TH) and peripheral blood (PB) of CTX-treated (CTX) (NZBxNZW) F1 mice with active disease compared to age-matched PBS-treated controls (Control). (A) Representative dot plots show 5-Bromo-2'-deoxyuridine (BrdU) incorporation of CD4+Foxp3+ Treg and of CD4+Foxp3- Tcon from CTX-treated and control mice in the respective compartments. The numbers in the quadrants indicate the percentage of the respective population among CD4+ cells. (B, C) Average percentage of BrdU+ cells among CD4+Foxp3- Tcon (B) and among CD4+Foxp3+ Treg (C). Data represent the means of four to five mice per group from two independent experiments. (D, E) Average percentage of CD4+Foxp3+ Treg among CD4+ T cells (D) and average absolute counts of CD4+Foxp3+ Treg in the respective organ (E). Data represent the means of five to ten mice per group from several independent experiments. (B-E) Error bars indicate standard error of the mean (SEM) (*P <0.05, **P <0.01, CTX vs Control).

Weigert et al. Arthritis Research & Therapy 2013 15:R35   doi:10.1186/ar4188
Download authors' original image